Search Results - Akash Nahar

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure

    KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure by Philippe Armand, John Kuruvilla, Jean‐Marie Michot, Vincent Ribrag, Pier Luigi Zinzani, Ying Zhu, Patricia Marinello, Akash Nahar, Craig H. Moskowitz

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

    Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087 by Robert Chen, Pier Luigi Zinzani, Hun Ju Lee, Philippe Armand, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Jianxin Lin, Eunhee Kim, Akash Nahar, Arun Balakumaran, Craig H. Moskowitz

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study

    Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgki... by Pier Luigi Zinzani, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz‐Kozik, Robin Gasiorowski, Nathalie A. Johnson, José Salvador Rodrigues de Oliveira, Valéria Buccheri, Guilherme Fleury Perini, Michael Dickinson, Andrew McDonald, Muhi̇t Özcan, Naohiro Sekiguchi, Monika Raut, Hilde Giezek, Akash Nahar, John Kuruvilla

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    886MO Health-related quality of life (HRQoL) from KEYNOTE-204: A phase III, randomized, open-label study of pembrolizumab (pembro) vs brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma (R/R cHL)

    886MO Health-related quality of life (HRQoL) from KEYNOTE-204: A phase III, randomized, open-label study of pembrolizumab (pembro) vs brentuximab vedotin (BV) in relapsed or refrac... by Pier Luigi Zinzani, Rod Ramchandren, Armando Santoro, Ewa Paszkiewicz‐Kozik, Robin Gasiorowski, Nathalie A. Johnson, José Salvador Rodrigues de Oliveira, Valéria Buccheri, Guilherme Fleury Perini, Michael Dickinson, Andrew McDonald, Muhi̇t Özcan, Naohiro Sekiguchi, Monika Raut, Ying Zhu, Akash Nahar, Patricia Marinello, John Kuruvilla

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    HEALTH‐RELATED QUALITY OF LIFE AMONG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL) IN A PHASE 3 STUDY OF PEMBROLIZUMAB VERSUS BRENTUXIMAB VEDOTIN

    HEALTH‐RELATED QUALITY OF LIFE AMONG PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL) IN A PHASE 3 STUDY OF PEMBROLIZUMAB VERSUS BRENTUXIMAB VEDOTIN by Pier Luigi Zinzani, Monika Raut, Todd L. Saretsky, Rod Ramchandren, Armando Santoro, Ewa Paszkiewicz‐Kozik, Robin Gasiorowski, Nathalie A. Johnson, José Salvador Rodrigues de Oliveira, Valéria Buccheri, Guilherme Fleury Perini, Michael Dickinson, Andrew McDonald, Muhi̇t Özcan, Naohiro Sekiguchi, Hilde Giezek, Akash Nahar, John Kuruvilla

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma

    Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma by Pier Luigi Zinzani, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz‐Kozik, Robin Gasiorowski, Nathalie A. Johnson, José Salvador Rodrigues de Oliveira, Valéria Buccheri, Guilherme Fleury Perini, Michael Dickinson, Andrew McDonald, Muhi̇t Özcan, Naohiro Sekiguchi, Ying Zhu, Monika Raut, Todd L. Saretsky, Akash Nahar, John Kuruvilla

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: